There are 1105 resources available
394P - Post-marketing study to evaluate the safety and efficacy of bevacizumab biosimilar in patients with advanced ovarian cancer
Presenter: K. H. Upveja
Session: Poster Display session
Resources:
Abstract
395P - Real-world safety of olaparib in ovarian cancer (OC): A retrospective, observational, database study in China
Presenter: Ning Li
Session: Poster Display session
Resources:
Abstract
396P - Real-world survival analysis of platinum-resistant recurrent ovarian cancer: A multi-center retrospective study from China
Presenter: Qing Wang
Session: Poster Display session
Resources:
Abstract
397P - Real-world outcome of dostarlimab in dMMR/MSI-H advanced/recurrent endometrial cancer: Updated results from Korean expanded access program
Presenter: Min Kyu Kim
Session: Poster Display session
Resources:
Abstract
398P - Real-world data of PARP inhibitors in first-line maintenance for BRCA mutated or HRD positive advanced ovarian cancer: A multicenter retrospective study from India
Presenter: Y Susheel Kumar
Session: Poster Display session
Resources:
Abstract
399P - Real-world experience of immunotherapy in metastatic dMMR endometrial cancer at a tertiary cancer center
Presenter: B.M Soumya
Session: Poster Display session
Resources:
Abstract
400TiP - An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Presenter: Jung-Yun Lee
Session: Poster Display session
Resources:
Abstract
401TiP - Adebrelimab plus chemotherapy and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab in platinum-sensitive relapsed ovarian cancer (CHANGCHUN): A single-arm, exploratory study
Presenter: Ziling Liu
Session: Poster Display session
Resources:
Abstract
414P - Prognostic factors of locally advanced hypopharyngeal cancer in Taiwan
Presenter: Tzu-Pin Lu
Session: Poster Display session
Resources:
Abstract
415P - Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer
Presenter: Ximei Zhang
Session: Poster Display session
Resources:
Abstract